Your Article Summary
See Latest ArticlesGenentech ordered to halt Rituxan trials
PharmExec, 06/19/09
An arbitrator has ruled that Genentech must halt several trials until Biogen Idec says they can move forward. In 2006, the two companies, filed for arbitration to settle whether Genentech could develop follow-on drugs to the cancer and rheumatoid arthritis drug Rituxan, without Biogen's approval. The arbitrator ruled that three of the trials must be halted, although a Phase III trial for the arthritis biologic ocrelizumab can continue.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09